Formycon

Random entry RSS

Posted in:
Regulatory

Planned Clinical Trial for Aflibercept Signals Likely Future Contests Over Regeneron’s Eylea®
By Spencer Johnson January 18, 2018 Comments are off
On January 3, 2018, Momenta and Mylan announced their development plan for a proposed biosimilar to Regeneron’s Eylea® whose active...

Read more

Tagged with: aflibercept, Clinical trial, Eylea®, Formycon, Momenta Pharmaceuticals, Mylan, Regeneron

http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
ShareEmail, Linked In, Twitter, Facebook, Google Plus

Back to Top